Diabetes, hyperglycemia and the management of cerebrovascular disease

Current Opinion in Neurology

Volumn 24, Issue 1, 2011, Pages 81-88

  Haratz, Salo ^a,b   Tanne, David ^b,c  

^a SHEBA MEDICAL CENTER   (Israel)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

cognitive impairment; dementia; diabetes; prediabetes; stroke

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; APOLIPOPROTEIN E4; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; HEMOGLOBIN A1C; INSULIN; PIOGLITAZONE; PLACEBO; POTASSIUM; TISSUE PLASMINOGEN ACTIVATOR;

ALZHEIMER DISEASE; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; COGNITIVE DEFECT; DEMENTIA; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EFFICACY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; STROKE;

EID: 78651387227     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/WCO.0b013e3283418fed     Document Type: Review

References (59)

1. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27:1047-1053.
2. Cowie CC, Rust KF, Ford ES, et al. Full accounting of diabetes and prediabetes in the U.S. population in 1988-1994 and 2005-2006. Diabetes Care 2009; 32:287-294.
3. Saczynski JS, Siggurdsson S, Jonsson PV, et al. Glycemic status and brain injury in older individuals: the age gene/environment susceptibility-Reykjavik study. Diabetes Care 2009; 32:1608-1613.
4. Sarwar N, Gao P, Seshasai SR, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of .102. prospective studies. Lancet 2010; 375:2215-2222.
5. Reeves MJ, Vaidya RS, Fonarow GC, et al. Quality of care and outcomes in patients with diabetes hospitalized with ischemic stroke: findings from Get With the Guidelines-Stroke. Stroke 2010; 41:e409-e417.
6. Andersen KK, Olsen TS. One-month to 10-year survival in the Copenhagen stroke study: interactions between stroke severity and other prognostic indicators. J Stroke Cerebrovasc Dis 2010 [Epub ahead of print].
7. Lu FP, Lin KP, Kuo HK. Diabetes and the risk of multisystem aging phenotypes: a systematic review and meta-analysis. PLoS One 2009; 4:e4144.
8. Knopman DS, Mosley TH, Catellier DJ, Coker LH. Fourteen-year longitudinal study of vascular risk factors, APOE genotype, and cognition: the ARIC MRI Study. Alzheimers Dement 2009; 5:207-214.
9. Verdelho A,Madureira S, Moleiro C, et al. White matter changes and diabetes predict cognitive decline in the elderly: the LADIS study. Neurology 2010; 75:160-167.
10. Ahtiluoto S, Polvikoski T, Peltonen M, et al. Diabetes, Alzheimer disease, and vascular dementia. A population-based neuropathologic study. Neurology 2010; 75:1195-1202.
11. Irie F, Fitzpatrick AL, Lopez OL, et al. Enhanced risk for Alzheimer disease in persons with type 2 diabetes and APOE epsilon4: the Cardiovascular Health Study Cognition Study. Arch Neurol 2008; 65:89-93.
12. Nooyens AC, Baan CA, Spijkerman AM, Verschuren WM. Type 2 diabetes mellitus and cognitive decline in middle-aged men and women -the Doetinchem Cohort Study. Diabetes Care 2010; 33:1964-1969.
13. Hyvarinen M, Qiao Q, Tuomilehto J, et al. Hyperglycemia and stroke mortality: comparison between fasting and 2-h glucose criteria. Diabetes Care 2009; 32:348-354.
14. Hyvarinen M, Tuomilehto J, Mahonen M, et al. Hyperglycemia and incidence of ischemic and hemorrhagic stroke: comparison between fasting and 2-h glucose criteria. Stroke 2009; 40:1633-1637.
15. Selvin E, Steffes MW, Zhu H, et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 2010; 362:800-811.
16. Vermeer SE, Sandee W, Algra A, et al. Impaired glucose tolerance increases stroke risk in nondiabetic patients with transient ischemic attack or minor ischemic stroke. Stroke 2006; 37:1413-1417.
17. Tanne D, Koren-Morag N, Goldbourt U. Fasting plasma glucose and risk of incident ischemic stroke or transient ischemic attacks: a prospective cohort study. Stroke 2004; 35:2351-2355.
18. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010; 33:S62-S69.
19. Matsuzaki T, Sasaki K, Tanizaki Y, et al. Insulin resistance is associated with the pathology of Alzheimer disease. The Hisayama Study. Neurology 2010; 75:764-770.
20. Whitmer RA, Karter AJ, Yaffe K, et al. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA 2009; 301:1565-1572.
21. Bobbert T, Mai K, Fischer-Rosinsky A, et al. A1C is associated with intimamedia thickness in individuals with normal glucose tolerance. Diabetes Care 2010; 33:203-204.
22. Park HY, Kyeong H, Park DS, et al. Correlation between insulin resistance and intracranial atherosclerosis in patients with ischemic stroke without diabetes. J Stroke Cerebrovasc Dis 2008; 17:401-405.
23. Tanne D, Tenenbaum A, Boyko V, et al. Increased insulin resistance and risk of incident cerebrovascular events in patients with preexisting atherothrombotic disease. Eur J Neurol 2009; 16:1217-1223.
24. Ronnemaa E, Zethelius B, Sundelof J, et al. Impaired insulin secretion increases the risk of Alzheimer disease. Neurology 2008; 71:1065-1071.
25. Ronnemaa E, Zethelius B, Sundelof J, et al. Glucose metabolism and the risk of Alzheimer's disease and dementia: a population-based 12 year follow-up study in 71-year-old men. Diabetologia 2009; 52:1504-1510.
26. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120:1640-1645.
27. Najarian RM, Sullivan LM, Kannel WB, et al. Metabolic syndrome compared with type 2 diabetes mellitus as a risk factor for stroke: the Framingham Offspring Study. Arch Intern Med 2006; 166:106-111.
28. Gupta AK, Dahlof B, Sever PS, Poulter NR. Metabolic syndrome, independent of its components, is a risk factor for stroke and death but not for coronary heart disease among hypertensive patients in the ASCOT-BPLA. Diabetes Care 2010; 33:1647-1651.
29. Boden-Albala B, Sacco RL, Lee HS, et al. Metabolic syndrome and ischemic stroke risk: Northern Manhattan Study. Stroke 2008; 39:30-35.
30. Koren-Morag N, Goldbourt U, Tanne D. Relation between the metabolic syndrome and ischemic stroke or transient ischemic attack: a prospective cohort study in patients with atherosclerotic cardiovascular disease. Stroke 2005; 36:1366-1371.
31. Kwon HM, Kim BJ, Park JH, et al. Significant association of metabolic syndrome with silent brain infarction in elderly people. J Neurol 2009; 256:1825-1831.
32. Raffaitin C, Gin H, Empana JP, et al. Metabolic syndrome and risk for incident Alzheimer's disease or vascular dementia: the Three-City Study. Diabetes Care 2009; 32:169-174.
33. Solfrizzi V, Scafato E, Capurso C, et al. Metabolic syndrome and the risk of vascular dementia: the Italian Longitudinal Study on Ageing. J Neurol Neurosurg Psychiatry 2010; 81:433-440.
34. Yaffe K, Weston AL, Blackwell T, Krueger KA. The metabolic syndrome and development of cognitive impairment among older women. Arch Neurol 2009; 66:324-328.
35. Palmer CN, Kimber CH, Doney AS, et al. Combined effect of inflammatory gene polymorphisms and the risk of ischemic stroke in a prospective cohort of subjects with type 2 diabetes: A Go-DARTS Study. Diabetes 2010 [Epub ahead of print].
36. Van Elderen SG, de Rooss A, de Craen AJ, et al. Progression of brain atrophy and cognitive decline in diabetes mellitus: a 3-year follow-up. Neurology 2010; 75:997-1002.
37. Segura B, Jurado MA, Freixenet N, et al. Microstructural white matter changes in metabolic syndrome: a diffusion tensor imaging study. Neurology 2009; 73:438-444.
38. Wu W, Brickman AM, Luchsinger J, et al. The brain in the age of old: the hippocampal formation is targeted differentially by diseases of late life. Ann Neurol 2008; 64:698-706.
39. Baker LD, Cross DJ, Minoshima S, et al. Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes. Arch Neurol 2010 [Epub ahead of print].
40. Holman RR, Paul SK, Bethel MA, et al. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359:1577-1589.
41. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358:2545-2559.
42. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358:2560-2572.
43. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360:129-139.
44. Marso SP, Kennedy KF, House JA, McGuire DK. The effect of intensive glucose control on all-cause and cardiovascular mortality, myocardial infarction and stroke in persons with type 2 diabetes mellitus: a systematic review and meta-analysis. Diab Vasc Dis Res 2010; 7:119-130.
45. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358:580-591.
46. Sone H, Tanaka S, Iimuro S, et al. Long-term lifestyle intervention lowers the incidence of stroke in Japanese patients with type 2 diabetes: a nationwide multicentre randomised controlled trial (the Japan Diabetes Complications Study). Diabetologia 2010; 53:419-428.
47. Kernan WN, Inzucchi SE, Viscoli CM, et al. Pioglitazone improves insulin sensitivity among nondiabetic patients with a recent transient ischemic attack or ischemic stroke. Stroke 2003; 34:1431-1436.
48. Wilcox R, Bousser MG, Betteridge DJ, et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events). Stroke 2007; 38:865-873.
49. Fuentes B, Ortega-Casarrubios MA, Sanjose B, et al. Persistent hyperglycemia >155 mg/dL in acute ischemic stroke patients: how well are we correcting it? Implications for outcome. Stroke 2010; 41:2362-2365.
50. Yong M, Kaste M. Dynamic of hyperglycemia as a predictor of stroke outcome in the ECASS-II trial. Stroke 2008; 39:2749-2755.
51. Ntaios G, Egli M, Faouzi M, Michel P. J-shaped association between serum glucose and functional outcome in acute ischemic stroke. Stroke 2010; 41:2366-2370.
52. Stead LG, Gilmore RM, Bellolio MF, et al. Hyperglycemia as an independent predictor of worse outcome in nondiabetic patients presenting with acute ischemic stroke. Neurocrit Care 2009; 10:181-186.
53. Paciaroni M, Agnelli G, Caso V, et al. Acute hyperglycemia and early hemorrhagic transformation in ischemic stroke. Cerebrovasc Dis 2009; 28:119-123.
54. Tanne D, Kasner SE, Demchuk AM, et al. Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the Multicenter rt-PA Stroke Survey. Circulation 2002; 105:1679-1685.
55. Uyttenboogaart M, Koch MW, Stewart RE, et al. Moderate hyperglycaemia is associated with favourable outcome in acute lacunar stroke. Brain 2007; 130:1626-1630.
56. McCormick M, Hadley D, McLean JR, et al. Randomized, controlled trial of insulin for acute poststroke hyperglycemia. Ann Neurol 2010; 67:570-578.
57. Finfer S, Chittock DR, Su SY, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009; 360:1283-1297.
58. Wiener RS, Wiener DC, Larson RJ. Benefits and risks of tight glucose control in critically ill adults: a meta-analysis. JAMA 2008; 300:933-944.
59. Gray CS, Hildreth AJ, Sandercock PA, et al. Glucose-potassium-insulin infusions in the management of poststroke hyperglycaemia: the UK Glucose Insulin in Stroke Trial (GIST-UK). Lancet Neurol 2007; 6:397-406.